SN//Connect

Addressing Racial Disparities in Health Care

Latest News

The Evolution to BTK Inhibitors in CLL Treatment

Chronic lymphocytic leukemia (CLL) treatment used to be one-size-fits-all. Today, the approach has shifted to more targeted therapies, thanks to the introduction of the Bruton's tyrosine kinase (BTK) inhibitors. Dr. James Gerson, hematologist-oncologist at Penn Medicine, tells SurvivorNet Connect that he prefers acalabrutinib (brand name: Calquence) because it has fewer side effects than ibrutinib in a similar patient population.

Learn More

BTK Inhibitors for CLL Patients: What Are the Risks?

Bruton’s tyrosine kinase (BTK) inhibitors have provided us with a more targeted way to treat leukemia and lymphoma patients. But, as with any other therapeutic option, they do have side effects. In general, second-generation BTK inhibitors such as zanubrutinib (brand name: Brukinsa) and acalabrutinib (brand name: Calquence) tend to have fewer adverse effects than the first-generation therapy, ibrutinib (brand name: Imbruvica).

Learn More

‘Great Urgency’ to Understand KRAS as an Actionable Marker in Lung Cancer

As cancer treatment evolves into precision medicine, certain markers are emerging as actionable targets for therapy, including G12C inhibitors for the KRAS gene. KRAS is considered to be the most mutated oncogene in human cancers. At least three different mutations in this gene are associated with lung cancer.

Learn More

Is a CT Scan Always Needed After Chemoradiation for Lung Cancer?

For patients with stage IIIB non-small cell lung cancer (NSCLC), treatment may start with chemoradiation. If the cancer remains under control after two or three of these treatments, durvalumab (brand name: Imfinzi) therapy can help keep it from progressing. Is it always necessary to do a post-treatment CT scan before prescribing Imfinzi?

Learn More

Importance of Monitoring Lung Cancer Patients on Imfinzi for Possible Pneumonitis

Durvalumab (brand name: Imfinzi) is the standard of care following chemoradiation for patients with stage III unresectable lung cancer. Patients who receive this and other checkpoint inhibitors will need careful monitoring for potential adverse immune events.

Learn More

Immune Therapies — The Future of Acute Lymphoblastic Leukemia Treatment

We have entered a new era of acute lymphoblastic leukemia (ALL) therapy. Targeted treatments use the patients’ own immune system to attack the cancer, and in the process, possibly avoid some of the side effects of chemotherapy. Three therapies in particular are having a significant impact on the treatment of ALL patients who have relapsed.

Learn More

CAR T-Cell Therapy in Acute Lymphoblastic Leukemia May Achieve ‘Deep Remission’

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (brand name: Kymriah) is an FDA-approved treatment for children and young adults with relapsed or refractory acute lymphoblastic leukemia.

Learn More

Managing Side Effects of Acute Lymphoblastic Leukemia Induction Chemotherapy

With induction chemotherapy, the aim is to put acute lymphoblastic leukemia (ALL) patients into complete remission. However, as these strong drugs kill cancer cells, they produce a number of side effects, some of which can be significant.

Learn More